Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury
Overview
Affiliations
Acute lung injury (ALI) is a severe illness with excess mortality and no specific therapy. In its early exudative phase, neutrophil activation and accumulation in the lung lead to hypoxemia, widespread tissue damage, and respiratory failure. In clinical trials, inhibition of proinflammatory mediators has not proven effective. In this study, we pursued a new investigative strategy that emphasizes mediators promoting resolution from lung injury. A new spontaneously resolving experimental murine model of ALI from acid aspiration was developed to identify endogenous proresolving mechanisms. ALI increased cyclooxygenase 2 (COX-2) expression in murine lung. Selective pharmacologic inhibition or gene disruption of COX-2 blocked resolution of ALI. COX-2-derived products increased levels of the proresolving lipid mediators lipoxin A4 (LXA4) and, in the presence of aspirin, 15-epi-LXA4. Both LXA4 and 15-epi-LXA4 interact with the LXA4 receptor (ALX) to mediate anti-inflammatory actions. ALX expression was markedly induced by acid injury and transgenic mice with increased ALX expression displayed dramatic protection from ALI. Together, these findings indicate a protective role in ALI for COX-2-derived mediators, in part via enhanced lipoxin signaling, and carry potential therapeutic implications for this devastating clinical disorder.
Song J, Cho J, Shin N, Yang M, Jung J, Hwang J Sci Rep. 2024; 14(1):25213.
PMID: 39448742 PMC: 11502745. DOI: 10.1038/s41598-024-75936-7.
Proresolving Lipid Mediators in the Respiratory System.
Serhan C, Levy B Annu Rev Physiol. 2024; 87(1):491-512.
PMID: 39303274 PMC: 11810588. DOI: 10.1146/annurev-physiol-020924-033209.
Offer S, Di Bucchianico S, Czech H, Pardo M, Pantzke J, Bisig C Part Fibre Toxicol. 2024; 21(1):38.
PMID: 39300536 PMC: 11411994. DOI: 10.1186/s12989-024-00600-x.
Aromadendrin Inhibits Lipopolysaccharide-Induced Inflammation in BEAS-2B Cells and Lungs of Mice.
Lee J, Park J, Choi J, Yun S, Rhee B, Jeong H Biomol Ther (Seoul). 2024; 32(5):546-555.
PMID: 39091099 PMC: 11392671. DOI: 10.4062/biomolther.2024.022.
Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies.
Moshawih S, Jarrar Q, Bahrin A, Lim A, Ming L, Goh H Heliyon. 2024; 10(3):e25734.
PMID: 38356603 PMC: 10864964. DOI: 10.1016/j.heliyon.2024.e25734.